Health Care Biotech and Pharmaceuticals


  • Traders work on the floor of the New York Stock Exchange underneath a board showing the name of Valeant Pharmaceuticals shortly before the opening of the markets in New York October 22, 2015.

    Bill Miller said the troubled pharmaceutical company should be worth about double its current trading price.

  • Bill Miller: Valeant could double

    Bill Miller, LMM LLC Chairman & CIO, talks about his view that stock in the beleaguered company Valeant Pharmaceuticals is worth at least $60.

  • Female scientist about to view a human sample under a microscope

    News of potential sanctions against blood-testing company Theranos was not surprising, business school professors told CNBC.

  • embryo

    Chinese researchers have reported successfully adding HIV-resistant mutations into human embryos, according to an article in Nature on Friday.

  • Bill Ackman

    Under-fire drug giant Valeant Pharmaceuticals International won't put Bausch & Lomb on the block, investor Bill Ackman told CNBC.

  • Biotech research microscope

    Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's "Power Lunch."

  • Financial engineering 'sucking money out of R&D': UTHR CEO

    Martine Rothblatt, United Therapeutics, weighs in on why the Treasury's tax inversion rule in good for big pharma. If the corporate tax rate was dropped in the U.S. then there would be no reason for inversions to go on, says Rothblatt.

  • Pfizer

    The inversion clampdown makes it more difficult for companies to stay competitive, says Sanford Bernstein's Ronny Gal.

  • Pfizer

    Pfizer is worth a lot more than it is trading at, based on the potential for future spin-offs, explains Bill Smead of Smead Capital Management.

  • Kenneth Frazier, CEO of Merck.

    Merck CEO Kenneth Frazier said a flawed corporate tax system drives inversion deals that have drawn the government's ire.

  • Merck CEO: Current tax system makes US companies uncompetitive

    Merck CEO Kenneth Frazier talks with CNBC's Meg Tirrell about his company's avoidance of tax inversion deals, as well as his views on the M&A environment and drug pricing.

  • Spallanzani is long Valeant

    Bill Ackman says he expects Pershing Square to regain most of its investment in Valeant, reports CNBC's Mary Thompson. John Spallanzani, GFI Group, weighs in.

  • A logo sits on the lab coat of a technician as he works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc.

    The Pfizer, Allergan merger effort has reignited a debate over corporate inversions, says Yevgeniy Feyman. But US jobs are not really at stake.

  • Coca-Cola COKE

    A failed $160 billion merger between Pfizer and Allergan left experts contemplating whether more deals could be hit by new tax rules.

  • Bill Ackman

    Billionaire investor William Ackman faced close questioning on Wednesday when he detailed his hedge fund's biggest-ever quarterly loss.

  • Brent Saunders, president and CEO of Allergan.

    CEO Brent Saunders spoke after Pfizer and Allergan terminated their $160B merger because of surprise changes in U.S. tax regulations.

  • The headquarters of Valeant Pharmaceuticals International in Laval, Quebec.

    Valeant Pharmaceuticals said a committee completed a review of its accounting practices and did not find anything that would require restatements.

  • Biotech

    Raghuram Selvaraju from Rodman & Renshaw explains that Pfizer could have second thoughts about acquiring Allergan if tax benefits are negated.

  • The "Fast Money" traders give their final trades of the day.

  • Time to bet on biotech?

    Les Funtleyder, E Squared Asset Management Portfolio Manager, and David Seaburg, Cowen & Company Managing Director and Head of Sales & Trading, discuss the biotech sector and how investors should approach it.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.


  • Dan Mangan is a reporter covering health care for

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.